ANDA 77587, held by Chartwell RX. Galantamine Hydrobromide.
As of Nov 21, 2026, ANDA 77587 (Galantamine Hydrobromide), held by Chartwell RX, was first approved by FDA on Jul 9, 2009, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 9, 2009 | Original application | Approved | None posted |
| Galantamine HydrobromideEQ 4MG BASE · tablet;oral | Galantamine Hydrobromide | Discontinued |
| Galantamine HydrobromideEQ 8MG BASE · tablet;oral | Galantamine Hydrobromide | Discontinued |
| Galantamine HydrobromideEQ 12MG BASE · tablet;oral | Galantamine Hydrobromide | Discontinued |
| Jun 28, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 14, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 9, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters